1. Medtech Insight
  2. >>Policy & Regulation

Quibim Extends Into US Market With FDA Authorization Of QP-Prostate CAD

AI Radiology Tool For Prostate Cancer Lesion Detection

 
• By Natasha Barrow

The US FDA's clearance of QP-Prostate CAD positions the company to support US health care providers and growing markets for fusion biopsy and focal therapy, said Quibim CEO and founder Angel Alberich-Bayarri.

prostate cancer imaging
(Shutterstock)

Quibim, a health tech startup designing AI tools to unlock clinical imaging data, received US Food and Drug Administration authorization for its QP-Prostate computer-aided detection (CAD) solution for the detection of prostate cancer lesions on MRI scans on 19 March.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Startups & SMEs